High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study
about
Ischaemic postconditioning: cardiac protection after the eventPostconditioning signalling in the heart: mechanisms and translatabilityDid clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?Erythropoietin action in stress response, tissue maintenance and metabolism.The effect of erythropoietin on normal and neoplastic cells.Human endothelial stem/progenitor cells, angiogenic factors and vascular repair.Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction.Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.Conditioning the heart to prevent myocardial reperfusion injury during PPCIErythropoietin and the heart: facts and perspectives.Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.New strategies for the management of no-reflow after primary percutaneous coronary intervention.Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials.Erythropoietin: a future therapy for failing hearts?Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review.Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy.What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials.Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis.Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury.High-dose erythropoietin for tissue protection.Harms of off-label erythropoiesis-stimulating agents for critically ill people.Signaling Pathways in Cardiac Myocyte Apoptosis.Angiogenic growth factors in myocardial infarction: a critical appraisal.Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial.Long term effects of epoetin alfa in patients with ST- elevation myocardial infarction.Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion.
P2860
Q26853129-1AEB3341-587C-4271-8DCC-04A0289902DDQ27021021-FDB5DFC3-F0D8-4D6F-8B91-551C54F98A87Q31056941-DA5BA24A-1400-41B9-9ADC-FBE57F7C46EBQ33907747-A5FD03D9-224A-4575-8EE9-ECFE5DCA4FCCQ34291437-251E6CF5-13AF-4E13-BA70-C9D804A514D5Q34333348-6812D9AD-0208-441B-8D5F-8E0E2FAF64CBQ34479931-B08C0213-03C1-4009-A774-592F46B54166Q34504572-9D957D71-A267-41EB-8D49-8571151E42ACQ35008662-1CE16B7A-C168-4257-BFEF-910E1C5C87D3Q35217404-ACF55F5D-8BCE-4E02-A0BF-A036955FD78AQ35705440-2D5F2D6A-B7FB-4715-8A86-E50C2268D12AQ36288965-E0A05027-F3FA-49C2-A722-80829420CF12Q36364317-5B633315-6102-4B18-8A03-862DD470AFEBQ37140973-74AFE5C5-6DD9-4C2D-937B-EF0B6F79BFE1Q37798565-46D29F59-478E-4F1C-B380-F36A8425F035Q37871920-4ED892D0-F9E4-4D76-8314-15C57EC391A3Q37880139-9308BD87-20F4-4E2C-A204-5D762FECD33FQ37946499-176619BA-7C7C-4995-A59B-0F9C265A59C4Q37952603-65FCE122-696D-4F79-95CD-BD9F07B60230Q37956569-16CF8293-1615-47B0-8083-55DA66D33458Q38010782-1C74D5D5-26FD-4EE2-9512-17C4B84459E7Q38108537-257E0790-5832-4F68-B864-59C1DB127F20Q38127584-F83A888F-FA6B-42B5-B6E8-07DAF7FB072EQ38137849-935D9136-6A87-4061-A269-9FE2463075CFQ38262836-1FAC0E83-0A7C-4F56-BAFA-89CDAC756C20Q38608377-4F9F2F92-09EF-4182-A678-B12951C349FAQ38768739-424F3B87-FF75-4626-B421-70DED45FF064Q39389842-6D5F1FEE-B2DF-45C8-AD27-6988C453DCCDQ39950250-9C6B4205-8DD8-4961-B735-91D9069CC966Q50893143-F457C226-A050-42DF-B55B-347518F3C33CQ50995309-ACF1FB89-4867-4B6F-9F2D-499AE2688922
P2860
High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study
description
im Februar 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 November 2009
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2011
@uk
name
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@en
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@nl
type
label
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@en
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@nl
prefLabel
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@en
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@nl
P2093
P50
P921
P1476
High-dose erythropoietin in pa ...... ised, placebo-controlled study
@en
P2093
Alessandra Bertoletti
Alessandra Repetto
Arturo Raisaro
Barbara Marinoni
Claudia Raineri
Enza Moretti
Ezio Bramucci
Luigi Angoli
Luigi Tavazzi
Marco Ferlini
P304
P356
10.1016/J.IJCARD.2009.10.028
P407
P50
P577
2009-11-10T00:00:00Z